Testing pembrolizumab plus lenvatinib before kidney cancer surgery
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether giving pembrolizumab (an immune medicine) and lenvatinib (a targeted medicine) before surgery can shrink or better treat renal cell carcinoma. The goal is to improve surgical outcomes and help the body fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have confirmed renal cell carcinoma (kidney cancer) from a biopsy done during screening.
- Your imaging shows the tumor can be surgically removed (stage cT2 to cT4), and if lymph nodes are involved, the surgeon says it’s still resectable.
- Your general health is good enough for treatment (ECOG 0 to 1).
- Your blood pressure is controlled (about 150/90 or less) and stays stable for about 1 week before starting.
- Your heart and other organ tests are adequate, including no major heart problems and acceptable heart pumping strength.
- You have not had certain prior treatments and you do not have key medical conditions that increase risk (for example, metastatic disease, serious lung inflammation, or active infections).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests two drugs, lenvatinib and pembrolizumab, given before surgery to shrink kidney cancer that has spread into the large vein carrying blood to the heart (the vena cava). The goal is to see if this approach makes surgery more effective and improves outcomes.
This Phase 2 trial tests whether pembrolizumab plus axitinib can shrink kidney cancer before surgery, when there is tumor growth into the inferior vena cava (IVC). It may help make the operation easier and improve chances of long-term control.
This study tests whether taking axitinib plus an immunotherapy drug (PD-1) before surgery can help people with kidney cancer live longer without the cancer coming back. It’s focused on people who have a higher-risk kidney tumor based on scans and pathology findings.
This trial tests whether personalized monitoring of cancer DNA in your blood (MRD) can guide treatment decisions after kidney cancer surgery. If MRD is detected, you may receive extra immunotherapy to reduce the risk of cancer returning.
This trial tests a combination of two drugs, cardenilimab and lenvatinib, given before and after surgery to remove kidney cancer. The goal is to see if this approach helps prevent the cancer from coming back. It is for people with early-stage (non-spread) clear cell kidney cancer who are healthy enough for surgery.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.